Gencurix's Study Explores the Difference between GenesWell BCT and Oncotype DX
Bioportfolio,
SEOUL, South Korea, Aug. 23, 2019 /PRNewswire/ -- Gencurix, Inc., a molecular diagnostics company, announced the publication of…
Gencurix's study explores GenesWell BCT and Oncotype DX differences
BioSpectrum,
A new study on Frontiers in Oncology comparing GenesWell(TM) BCT, a prognostic multigene test, with Genomic Health's Oncotype…
Gencurix's Study Explores the Difference between GenesWell BCT and Oncotype DX
PharmiWeb,
SEOUL, South Korea, Aug. 23, 2019 /PRNewswire/ -- Gencurix, Inc., a molecular diagnostics company, announced the publication of…
Gencurix's Study Explores the Difference between GenesWell BCT and Oncotype DX
BioTech Gate,
SEOUL, South Korea, Aug. 23, 2019 /PRNewswire/ -- Gencurix, Inc., a molecular diagnostics company, announced the publication of…